Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
12:11pm, Tuesday, 28'th Oct 2025
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript
11:41am, Tuesday, 28'th Oct 2025
Incyte Corporation (NASDAQ:INCY ) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Alexis Smith William Meury - CEO, President & Director Pablo Cagnoni - President and Head of R
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
10:30am, Tuesday, 28'th Oct 2025
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compar
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Oct 2025
Incyte (INCY) came out with quarterly earnings of $2.26 per share, beating the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.07 per share a year ago.
Incyte boosts annual sales forecast of blood cancer drug after strong quarter
08:02am, Tuesday, 28'th Oct 2025
Drugmaker Incyte Corp on Tuesday raised its annual sales forecast for its blood cancer treatment Jakafi after robust demand for the drug helped the company surpass Wall Street estimates for third-quar
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Tuesday, 28'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates.
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
07:30am, Monday, 27'th Oct 2025
WILMINGTON, Del. & CINCINNATI--(BUSINESS WIRE)---- $INCY--Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System.
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
07:55pm, Saturday, 25'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ISAD2025--Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis.
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
11:02am, Friday, 24'th Oct 2025
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Thursday, 23'rd Oct 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Incyte: Strong Growth, Margin Expansion, And Low Valuation
11:13pm, Tuesday, 21'st Oct 2025
Incyte Corporation offers strong growth potential and a low valuation, driven by expanding margins and a robust earnings outlook. INCY's revenue is anchored by Jakafi, but a diverse pipeline and poten
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 21'st Oct 2025
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Corporation (NASDAQ:INCY ) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer October 19, 2025 1:30 PM EDT Company Particip
Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice
01:00pm, Monday, 20'th Oct 2025
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
